L-myc, GST M1 genetic polymorphism and hepatocellular carcinoma risk among chronic hepatitis B carriers

Cancer Lett. 1996 Jun 5;103(2):171-6. doi: 10.1016/0304-3835(96)04209-7.

Abstract

In order to assess associations between the genetic polymorphism of L-myc and glutathione S-transferase M1 (GST M1) and the risk of hepatocellular carcinoma (HCC), a total of 46 surgically treated HCC patients who were seropositive in hepatitis B surface antigen (HBsAg) and 88 HBs-Ag positive controls were recruited for this study. L-myc and GST M1 genetic polymorphism was examined using a polymerase chain reaction-based restriction fragment length polymorphism assay on DNA extracted from liver and peripheral blood samples. There was no significant difference in GST M1 genotypes between HCC patients and matched controls. A gene dosage trend of association with HCC risk was observed for L-myc genotype. The dose-response relationship remained statistically significant in the multiple logistic regression analysis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Base Sequence
  • Carcinoma, Hepatocellular / etiology*
  • Carcinoma, Hepatocellular / genetics
  • Carrier State
  • Case-Control Studies
  • Chronic Disease
  • DNA Primers / chemistry
  • Female
  • Genes, myc*
  • Glutathione Transferase / genetics*
  • Hepatitis B / genetics*
  • Humans
  • Liver Neoplasms / etiology*
  • Liver Neoplasms / genetics
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Odds Ratio
  • Polymerase Chain Reaction
  • Polymorphism, Genetic
  • Polymorphism, Restriction Fragment Length
  • Risk Factors

Substances

  • DNA Primers
  • Glutathione Transferase